Results 131 to 140 of about 1,005 (173)
Adjuvant Pitolisant in a Case With Early-Onset Schizophrenia
Clinical Neuropharmacology, 2021 Early-onset schizophrenia is notorious for poor prognostication and treatment refractoriness. Child/adolescent psychiatric population, by virtue of age, is at a heightened risk for cardiometabolic risk of atypical antipsychotics. Available pharmacological options are, sorely, too limited to mitigate this risk.The authors are reporting here on an ...
Ahmed, Naguy +2 more
openaire +3 more sources
Pitolisant: Pediatric First Approval
Pediatric Drugs, 2023 Pitolisant (WAKIX®), a histamine H3 receptor antagonist/inverse agonist that has been developed by Bioprojet Pharma, is approved in the EU and USA and elsewhere for use in adults with narcolepsy with or without cataplexy. In February 2023, based on clinical data in patients aged 6 to < 18 years, pitolisant received its first approval in adolescents and
Susan Keam (4873372)
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pitolisant and intravenous cocaine self-administration in mice
European Journal of Pharmacology, 2019Pitolisant, a selective inverse agonist for the histamine H3 receptor, is a new treatment for adults suffering from narcolepsy. Numerous studies have shown that striatal H3 receptors can modulate the activity of the dopamine mesolimbic system, a neuronal pathway that plays a crucial role in drug addiction.
Ezio Tirelli
exaly +3 more sources
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial [PDF]
American Journal of Respiratory and Critical Care Medicine, 2020 : Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the ...
Yves Dauvilliers +2 more
exaly +5 more sources
Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
Sleep, 2019 International audienceStudy objectives: To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy.Methods: This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and ...
Isabelle Lecomte +2 more
exaly +3 more sources
Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort [PDF]
Neurological Sciences, 2022 Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities.
Valerio Brunetti +2 more
exaly +4 more sources
SLEEP, 2023
Abstract Introduction WAKIX (pitolisant) is a potent and highly selective histamine 3 receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Anthony Adamkovic +4 more
openaire +1 more source
Abstract Introduction WAKIX (pitolisant) is a potent and highly selective histamine 3 receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Anthony Adamkovic +4 more
openaire +1 more source
Pitolisant Hydrochloride (Wakix)
Canadian Journal of Health Technologies, 2022CADTH recommends that Wakix not be reimbursed by public drug plans for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. It is still not known whether Wakix offers any therapeutic benefit over other treatments used for EDS or cataplexy.
openaire +1 more source
Drug and Therapeutics Bulletin, 2017
▼Pitolisant (Wakix—Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.1 Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
openaire +2 more sources
▼Pitolisant (Wakix—Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.1 Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
openaire +2 more sources
Pitolisant: First Global Approval
Drugs, 2016Pitolisant (Wakix™) is an inverse agonist of the histamine H3 receptor that is being developed by Bioproject. Oral pitolisant is approved in the EU for the treatment of narcolepsy with or without cataplexy in adults. Pitolisant has received a Temporary Authorization of Use in France for this indication in case of treatment failure, intolerance or ...
openaire +4 more sources